No black box warning on record for Imlygic
As of the latest FDA labeling reviewed, Imlygic (TALIMOGENE LAHERPAREPVEC) does not carry a black box warning. Standard warnings and precautions still apply — see the full Imlygic medicine page for the complete safety profile.